image imagewidth (px) 230 933 | latex stringlengths 184 5.27k | filename stringlengths 17 19 |
|---|---|---|
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|l|l|l|l|}
\hline
\textbf{Scale} & \multicolumn{4}{|l|}{\textbf{Self-report}} & \multicolumn{4}{|l|}{\textbf{Proxy-report}} \\
\hline
& \textbf{N} & \textbf{Mean (sd)} & \textbf{df} & \textbf{F} & \textbf{N} & \textbf{Mean (sd)} & \textbf{df} & \textbf{F} \\
\hl... | PMC1079918_table_2 | |
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|}
\hline
\textbf{Functional type} & \textbf{Fluffy tails (F$>$2)} & \textbf{No fluffy tails (F$<$2)} & \textbf{Positive rate} & \textbf{Negative rate} \\
\hline
Regulatory regions & 51 & 9 & 85 \% & 15 \% \\
\hline
Exons & 1 & 59 & 1.6 \% & 98.4 \% \\
\hline
Non... | PMC1127108_table_1 | |
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|}
\hline
\textbf{Proliferation marker} & \textbf{rs} & \textbf{P} \\
\hline
Thymidylate synthase & 0.38 & $<$0.001 \\
\hline
Thymidine kinase 1 & 0.23 & $<$0.01 \\
\hline
Survivin & 0.22 & $<$0.01 \\
\hline
E2F & 0.22 & $<$0.01 \\
\hline
Topoisomerase II$\alpha$ & 0... | PMC1175052_table_2 | |
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|}
\hline
\textbf{EM operation} & \textbf{Definition} \\
\hline
Overlap (x ❍ y) & x and y overlap if they have a part in common. \\
\hline
Disjoint (x ι y) & x and y are disjoint if they share no parts in common. \\
\hline
Binary product (x . y) & The parts that x and ... | PMC1175956_table_1 | |
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|l|l|}
\hline
& \multicolumn{3}{|l|}{\textbf{Low A}} & \multicolumn{3}{|l|}{\textbf{Low B}} \\
\hline
& \textbf{Observed} & \textbf{RR} & \textbf{p-value} & \textbf{Observed} & \textbf{RR} & \textbf{p-value} \\
\hline
Not Adjusted & 440 & 0.81 & 0.004 & * & * &... | PMC1180846_table_1 | |
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|}
\hline
\textbf{Group} & \textbf{Patient Number} & \textbf{Follow up (months)} & \textbf{Raised IOP} & \textbf{Stepwise in last retinopathy FU (ETDRS) deterioration grade at} \\
\hline
A & 1 & 15 & & 3 \\
\hline
& & 14 & & 1 \\
\hline
A & 2 & 6 & & 0 \\
\h... | PMC1183218_table_2 | |
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|l|l|l|l|}
\hline
\textbf{Source} & \multicolumn{2}{|l|}{\textbf{dChip}} & \multicolumn{2}{|l|}{\textbf{MAS 5.0}} & \multicolumn{2}{|l|}{\textbf{RMA}} & \multicolumn{2}{|l|}{\textbf{GCRMA-EB}} \\
\hline
& \textbf{Mean} & \textbf{SD} & \textbf{Mean} & \textbf{SD}... | PMC1232851_table_0 | |
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|l|l|l|l|l|l|l|}
\hline
& \textbf{Cont 3 M} & \textbf{Cont 6 M} & \textbf{Cont 11 M} & \textbf{Cont 21 M} & \textbf{Inulin 3 M} & \textbf{Inulin 6 M} & \textbf{Inulin 11 M} & \textbf{Inulin 21 M} & \textbf{inulin} & \textbf{age} & \textbf{interaction} \\
\hline
... | PMC1283151_table_4 | |
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|}
\hline
\textbf{Type of post consultation letter} & \textbf{Letter to General Practitioner} & \textbf{Letter to patient} & \textbf{Significance (Wilcoxin Signed Ranks test)} \\
\hline
Length (minutes of $\pm$ time SD, to n) dictate letter & 3.28 $\pm$ 2.2, 81 & 2... | PMC1360088_table_0 | |
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|l|l|l|l|}
\hline
& \multicolumn{2}{|l|}{\textbf{dvSalt30}} & \multicolumn{2}{|l|}{\textbf{ecox}} & \multicolumn{2}{|l|}{\textbf{shHeat5}} & \multicolumn{2}{|l|}{\textbf{shCold5}} \\
\hline
\textbf{Method} & \textbf{\#Genes} & \textbf{\%Agree} & \textbf{\#Genes}... | PMC1397872_table_1 | |
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|l|l|l|l|l|l|}
\hline
\textbf{AAA model} & \textbf{P (mmHg)} & \textbf{dAAA,max (cm)} & \textbf{Thickness (cm) t} & \textbf{$\alpha$} & \textbf{$\beta$} & \textbf{(Authors' results) Stress (MPa)} & \multicolumn{2}{|l|}{\textbf{Modified Equation Laplace}} & \multi... | PMC1421417_table_0 | |
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|}
\hline
\textbf{Effect Size} & \textbf{Failure Rate 95\%} & \textbf{Failure Rate 98\%} \\
\hline
30\% & 235 & 195 \\
\hline
33.3\% & 185 & 160 \\
\hline
35\% & 160 & 140 \\
\hline
40\% & 120 & 95 \\
\hline
\end{tabular}}
\end{table} | PMC1459124_table_0 | |
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|l|l|}
\hline
\textbf{Source} & \textbf{DF} & \multicolumn{5}{|l|}{\textbf{F value}} \\
\hline
& & \textbf{Critical} & \textbf{Dorsal vein} & \textbf{Caudal vein} & \textbf{Dorsal artery} & \textbf{Caudal artery} \\
\hline
Family & 3 & 2.91 & 11.35* & 1.35 & 8.... | PMC1479343_table_0 | |
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|}
\hline
\textbf{Compound (µg/ml)} & \textbf{IL-8 released (pg/ml)} \\
\hline
Medium alone & 24.6 $\pm$ 1.5 \\
\hline
Tryptase 2.0 & 105.2 $\pm$ 5.3* \\
\hline
Elastase 0.3 & 108.4 $\pm$ 13.2* \\
\hline
Benzamidine 30 & 37.6 $\pm$ 4.4 \\
\hline
Leupeptine 30 & 27.4 $\... | PMC1489934_table_2 | |
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|}
\hline
\textbf{Variable} & \multicolumn{2}{|l|}{\textbf{Unemployment Duration (\%/n)}} & \textbf{t (p)} \\
\hline
& \textbf{Short-term N = 234} & \textbf{Long-term N = 195} \\
\hline
\multicolumn{4}{|l|}{Depression months) (in past 12} \\
\hline
Never & 15.8/37... | PMC1526724_table_1 | |
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|l|l|}
\hline
\textbf{Year} & \textbf{Estimated population\#} & \textbf{Birth cohort} & \textbf{Vaccination coverage*} & \textbf{Vaccine efficacy**} & \textbf{Children susceptible} & \textbf{Cumulated population susceptible} \\
\hline
1988 & 2,076,264 & 44,432 & ... | PMC1586205_table_1 | |
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|l|l|l|l|l|l|l|l|l|l|}
\hline
Class & \multicolumn{14}{|l|}{3 1065 [336]} \\
\hline
Subclass & 3.1 [113] 267 & \multicolumn{2}{|l|}{3.2 163 [56]} & 3.3 [4] 10 & 3.4 [49] 317 & 3.5 [70] 171 & 3.6 [36] 109 & 3.7 [4] 10 & 3.8 [1] 10 & 3.9 [1] 1 & 3.10 [1] 2 & 3.11 [... | PMC1609188_table_0 | |
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|l|}
\hline
\textbf{Authors} & \textbf{No. of Subjects} & \textbf{Test} & \textbf{Sensitivity (\%)} & \textbf{Specificity (\%)} & \textbf{QUADAS Score} \\
\hline
Thomas et al [24] & 297 & Kernig & 5* & 95* \\
\hline
& & & 9** & 96** & 7 \\
\hline
& & & 0***... | PMC1635718_table_7 | |
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|l|l|l|}
\hline
\textbf{Village} & \textbf{Paddy category} & \textbf{No. of Habitats} & \textbf{1stinstars} & \textbf{2nd instars} & \textbf{3rd instars} & \textbf{4th instars} & \textbf{Pupae} \\
\hline
Kangichiri & Ploughed & 25 & 1.41 & 0.95 & 0.09 & 0.00 & 0.... | PMC1636646_table_1 | |
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|}
\hline
& \multicolumn{2}{|l|}{\textbf{Respondents}} & \multicolumn{2}{|l|}{\textbf{Dropouts}} \\
\hline
\textbf{Characteristics at baseline} & \textbf{N} & \textbf{\%} & \textbf{N} & \textbf{\%} \\
\hline
\multicolumn{5}{|l|}{Age (years)} \\
\hline
$<$ 30 & 2... | PMC1693921_table_0 | |
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|}
\hline
\textbf{CDS} & \textbf{Gene name} & \textbf{Predicted function} & \textbf{m-value RES167} & \textbf{m-value CL1} \\
\hline
\multicolumn{5}{|l|}{BIOTIN BIOSYNTHESIS AND TRANSPORT} \\
\hline
cg0095 & bioB & biotin synthase & 3.69 & 1.55 \\
\hline
cg2147 &... | PMC1779776_table_0 | |
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|}
\hline
\textbf{Accession no} & \textbf{Symbol} & \textbf{Gene Name} & \textbf{Reference} \\
\hline
\multicolumn{4}{|l|}{Chemokines and receptors} \\
\hline
[genebank:NM_002983] & CCL3 & Chemokine, CC motif, Ligand 3 $\pi$ & [25] \\
\hline
[genebank:NM_002984] & ... | PMC1781469_table_0 | |
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|}
\hline
\textbf{Scoliosis} & \textbf{Karyotype} \\
\hline
12° Right thoracic, hypokyphosis & 45XO \\
\hline
30° Right Thoraco-lumbar & 45XO \\
\hline
18° Right thoracic, hypokyphosis & 46XisoX(q10) Mosaic \\
\hline
30° Right Thoraco-lumbar & 45XO \\
\hline
No Xrays M... | PMC1808441_table_2 | |
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|l|l|l|l|l|l|l|l|l|l|l|l|l|l|l|}
\hline
\textbf{$\delta$} & \textbf{C1} & \textbf{C2} & \textbf{C3} & \textbf{C4} & \textbf{C5} & \textbf{C6} & \textbf{C7} & \textbf{C8} & \textbf{C9} & \textbf{C} & \textbf{V} & \textbf{V1} & \textbf{V2} & \textbf{V3} & \textbf{V... | PMC1847453_table_1 | |
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|}
\hline
\textbf{Patient characteristics} & \multicolumn{3}{|l|}{\textbf{Group}} & \textbf{P-value} \\
\hline
& \textbf{Faculty physician (\%)} & \textbf{General doctor (\%)} & \textbf{Resident (\%)} \\
\hline
Mean age (SD), years & 50.39 (15.65) & 49.32 (15.86... | PMC1852109_table_1 | |
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|l|}
\hline
\textbf{Variables} & \textbf{N (\%)} & \textbf{Mean} & \textbf{Std. Deviation} & \textbf{Min} & \textbf{Max} \\
\hline
Gender & 12376 & - & - & - & - \\
\hline
Males & 5660 (45.3) & - & - & - & - \\
\hline
Females & 6716 (54.3) & - & - & - & - \\
\hli... | PMC1868752_table_0 | |
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|l|}
\hline
\textbf{Ages (years)} & \textbf{\% Seronegative} & \textbf{Risk among pregnancies* women/100 seronegative} & \textbf{Risk for pregnancies all women/100} & \textbf{pregnancies No. live-birth (100's)†} & \textbf{primary live-birth No. women infection pr... | PMC1925089_table_1 | |
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|l|l|}
\hline
\textbf{Drug usea} & \multicolumn{2}{|l|}{\textbf{Invasion}} & \multicolumn{2}{|l|}{\textbf{Noninvasive}} & \multicolumn{2}{|l|}{\textbf{TP53 IHC Intensity}} \\
\hline
& \textbf{Noninvasive OR (95\%CI)b} & \textbf{Invasive OR (95\%CI)b} & \textbf{L... | PMC2018698_table_3 | |
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|l|l|l|l|l|l|l|}
\hline
\textbf{. . . . Diseases} & \textbf{Age} & \multicolumn{2}{|l|}{\textbf{a}} & \multicolumn{2}{|l|}{\textbf{b}} & \multicolumn{2}{|l|}{\textbf{c}} & \multicolumn{4}{|l|}{\textbf{MAPE (\%)}} \\
\hline
\textbf{. . . .} & & & & & & & & ... | PMC2077810_table_1 | |
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|}
\hline
\textbf{Sample size} & \multicolumn{3}{|l|}{\textbf{Power}} & \textbf{Type I error} \\
\hline
& \textbf{$\beta$3 = -0.65} & \textbf{$\beta$3 = -0.95} & \textbf{$\beta$3 = -1.20} & \textbf{$\beta$3 = 0} \\
\hline
150 & 0.348 & 0.642 & 0.780 & 0.052 \\
\... | PMC2099440_table_0 | |
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|}
\hline
\textbf{. . . . VACCINE DOSE 1} & \multicolumn{2}{|l|}{\textbf{Group 1, n = 12}} & \multicolumn{2}{|l|}{\textbf{Group 2, n = 13}} \\
\hline
\textbf{. . . .} & \textbf{n} & \textbf{\%} & \textbf{n} & \textbf{\%} \\
\hline
. . . . Documented Fever .37.5 &... | PMC2204057_table_2 | |
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|}
\hline
\textbf{Class} & \textbf{Subclass} & \textbf{Number gene families of} & \textbf{Number of genes} & \textbf{Number pseudogenes of} \\
\hline
ANTP & HOXL & 14 & 52 & 0 \\
\hline
& NKL & 23 & 48 & 19b \\
\hline
PRD & PAX & 3 & 7a & 0 \\
\hline
& PAXL & 2... | PMC2211742_table_0 | |
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|l|l|l|l|}
\hline
\textbf{Group} & \multicolumn{4}{|l|}{\textbf{\% Concentration of parasitaemia1 of IgG (mg/ml)2}} & \multicolumn{4}{|l|}{\textbf{\% Concentration of invasion inhibition4 of IgG (mg/ml)}} \\
\hline
\\
\hline
& \textbf{0.5} & \textbf{0.25} & \te... | PMC2253826_table_0 | |
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|}
\hline
& \textbf{Tilburg} & \textbf{Groningen} \\
\hline
Number of contacts between 00.00 and 08.00 h & 787 & 483 \\
\hline
Number of contacts between 08.00 and 24.00 h & 3466 & 2028 \\
\hline
\end{tabular}}
\end{table} | PMC2265289_table_0 | |
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|}
\hline
\textbf{Estimators} & \multicolumn{2}{|l|}{\textbf{Lung cancer}} & \multicolumn{2}{|l|}{\textbf{Cervix cancer}} \\
\hline
& \textbf{Dispersion variance} & \textbf{Prediction variance} & \textbf{Dispersion variance} & \textbf{Prediction variance} \\
\hl... | PMC2276482_table_3 | |
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|}
\hline
\textbf{Variable} & \multicolumn{2}{|l|}{\textbf{Significance}} \\
\hline
\textbf{Muscle Total CoQ10 (mcg/mg) T2 pre ¥} & \textbf{r value} & \textbf{0.423} \\
\hline
& p value & 0.007 \\
\hline
Muscle Total CoQ10 (mcg/mg) T2 post & r value & 0.189 \\
\hlin... | PMC2315638_table_7 | |
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|}
\hline
\textbf{Coding regions} & \textbf{Number of genotypes} & \textbf{Minimum intragenotype similarity} & \textbf{Maximum intergenotype similarity} \\
\hline
N & 8* & 83,3 & 80,3 \\
\hline
& 7 & 80,3 & 79,8 \\
\hline
N,P,M,G,L & 8* & 81,6 & 76,4 \\
\hline
& ... | PMC2327259_table_2 | |
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|l|}
\hline
& & \textbf{N} & \textbf{Ne} & \textbf{H} & \textbf{He} \\
\hline
MCL1 & real time RT-PCR & 1 & 2.97 & 5.53 & 8.24 \\
\hline
& DNA microarray & 1 & 3.44 & 3.92 & 5.27 \\
\hline
BAK 1 & real time RT-PCR & 1 & 3.37 & 0.96 & 2.92 \\
\hline
& DNA micr... | PMC2330149_table_1 | |
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|l|l|l|l|l|l|l|l|}
\hline
\textbf{Step} & \textbf{No. SNPs} & \textbf{0} & \textbf{1} & \textbf{2} & \textbf{3} & \textbf{4} & \textbf{5} & \textbf{6} & \textbf{7} & \textbf{8} & \textbf{9} & \textbf{$\geq$10} \\
\hline
1 & Availablea & 1286 & 413 & 310 & 614 & 4... | PMC2367558_table_0 | |
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|l|l|l|l|l|l|l|l|l|l|}
\hline
\textbf{Genotypes} & \multicolumn{2}{|l|}{\textbf{Controls}} & \multicolumn{2}{|l|}{\textbf{All Patients}} & & & \multicolumn{4}{|l|}{\textbf{Premenopausal Patients}} & \multicolumn{4}{|l|}{\textbf{Postmenopausal Patients}} \\
\hli... | PMC2377277_table_2 | |
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|}
\hline
\textbf{Study} & \textbf{Outcome} & \textbf{Relative Risk/Incident Density Ratio (95\% CI)} \\
\hline
Luby, Agboatwalla et al 2004 [50] & Diarrhoea \\
\hline
RCT & Mean Incidence \\
\hline
Quality Score 6a & Antibiotic Soap & 0.50 (0.36, 0.63) \\
\hline
& ... | PMC2397399_table_2 | |
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|}
\hline
\textbf{Strain (a)} & \textbf{Mic-PCC7806} & \textbf{Mic-NIES843} \\
\hline
Genome length & 5.17 Mb (116 Contigs) & 5.84 Mb \\
\hline
rRNA loci & 2 & 2 \\
\hline
tRNA loci & 41 & 42 \\
\hline
Number of CDSs & 5292 & 6312 \\
\hline
Putative transposases (COG... | PMC2442094_table_0 | |
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|l|l|}
\hline
& \textbf{Lbx1/Tlx1 locus} & \textbf{Former Lbx4/Tlx4 locus} & \textbf{(Former locus Lbx3)/Tlx3} & \textbf{Lbx2/Tlx2 locus} & \textbf{Lbx-less Nkx3.2 locus} & \textbf{Lbx2/Tlx2 loci} \\
\hline
& & & & amniotes & tetrapods & teleosts \\
\hline
M... | PMC2446394_table_0 | |
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|}
\hline
\textbf{Characteristic} & \textbf{n (\%)a} \\
\hline
\multicolumn{2}{|l|}{Sex} \\
\hline
Male & 234 (55.7) \\
\hline
Female & 186 (44.3) \\
\hline
Age (years) & 68.2 $\pm$ 13.8 \\
\hline
$<$ 65 & 138 (32.9) \\
\hline
65–79 & 198 (47.1) \\
\hline
$\geq$ 80 & 8... | PMC2474854_table_0 | |
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|l|l|l|l|l|l|}
\hline
\textbf{Parameter [statistic]} & \textbf{patients All} & \multicolumn{3}{|l|}{\textbf{Olanzapine vs. non-olanzapine}} & \multicolumn{3}{|l|}{\textbf{Risperidone vs. non-risperidone}} & \multicolumn{3}{|l|}{\textbf{Haloperidol vs. non-haloper... | PMC2507712_table_1 | |
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|}
\hline
\textbf{Risk of dissatisfaction} & \textbf{Public (\%)} & \textbf{Private (\%)} & \textbf{All (\%)} \\
\hline
Properly identified specimen & 3/10(30.0) & 1/4(25.0) & 4/14(28.6) \\
\hline
Clear and accurate test request & 4/10 (40.0) & 2/4(50.0) & 6/14(42.... | PMC2518553_table_3 | |
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|}
\hline
\textbf{Gene Category} & \textbf{Genes Upregulated} & \textbf{Genes Downregulated} \\
\hline
Protein Transport & 6 & 2 \\
\hline
Ion Transport & 6 & 3 \\
\hline
Proliferation & 2 & 2 \\
\hline
Differentiation & 2 & 2 \\
\hline
Anti-apoptosis/Survival & 3 & ... | PMC2533024_table_0 | |
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|}
\hline
\textbf{Species} & \textbf{\# genes amplified1} & \textbf{\# disrupted genes} & \textbf{\% disrupted} \\
\hline
A449 & 162 & 16 & 100 \\
\hline
A449 cDNA & 16 & 16 & 100 \\
\hline
A. salmonicida subsp. salmonicida ATCC 33658T & 15 & 15 & 100 \\
\hline
A. ... | PMC2556355_table_2 | |
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|}
\hline
\textbf{Characteristic} & \textbf{PD (n = 57)} & \textbf{Controls (n = 51)} \\
\hline
Age at study (mean6SD), years & 62.369.1 & 63.768.7 \\
\hline
Age at onset (mean6SD), years & 58.269.1 & N/A \\
\hline
Range of age at onset, years & 40–75 & N/A \\
\hline... | PMC2559870_table_0 | |
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|}
\hline
\textbf{Stage of labour} & \textbf{Definition of stage and phase} & \textbf{Diagnostic Criteria for Dystocia} \\
\hline
First stage & From cervical onset dilatation of regular to full contractions dilatation of leading cervix to \\
\hline
Latent phase & Cer... | PMC2569907_table_0 | |
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|}
\hline
\textbf{Lipid variable} & \textbf{Educational status} & \textbf{Obesity} & \textbf{Truncal obesity} \\
\hline
Total Cholesterol $\geq$ 200 mg/dl & 0.450 (0.072) & 0.322 (0.120) & 0.773 (0.011) \\
\hline
LDL Cholesterol $\geq$ 130 mg/dl & 0.529 (0.051) & 0... | PMC2579290_table_3 | |
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|l|l|}
\hline
\textbf{Analyses} & \textbf{Dose Group} & \multicolumn{3}{|l|}{\textbf{Proportion of Responders}} & \multicolumn{2}{|l|}{\textbf{SBA Titers four weeks after vaccination}} \\
\hline
& & \textbf{n/N} & \textbf{\%} & \textbf{95\% CI} & \textbf{GMT} &... | PMC2584372_table_2 | |
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|}
\hline
\textbf{Substance} & \textbf{Sham} & \textbf{Saline} & \textbf{LPS} & \textbf{Kruskal-Wallis H(2, N = 33)} \\
\hline
\multicolumn{5}{|l|}{Alkanes} \\
\hline
Octadecane & 0,17 $\pm$ 0,11 & 0,18 $\pm$ 0,05 & 0,19 $\pm$ 0,11 & NS \\
\hline
Nonadecane & 0,2... | PMC2596086_table_0 | |
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|}
\hline
\textbf{Species} & \textbf{Mineralization of the permanent dentition at birth} & \textbf{Reference} \\
\hline
\multicolumn{3}{|l|}{Category I. Altricial: eyes closed, naked, nidicolous or ‘nest-dwelling’} \\
\hline
Gray short-tail opossum, Monodelphis domes... | PMC2629576_table_2 | |
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|}
\hline
\textbf{Family} & \textbf{Members} \\
\hline
1 & mir-466b-1 mir-466b-2 \\
\hline
2 & mir-664-1 mir-664-2 \\
\hline
\end{tabular}}
\end{table} | PMC2632650_table_3 | |
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|}
\hline
\textbf{Term} & \textbf{Description and synonyms} \\
\hline
LRTI & Lower pneumonia. very severe respiratory pneumonia. Includes tract all infection. cases identified Used synonymously as mild, severe with or \\
\hline
All-cause LRTI & Non-specific lower respi... | PMC2635480_table_0 | |
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|}
\hline
\textbf{Experiment No.} & \textbf{(Theoretical) Open Voltage-V circuit} & \textbf{Open ( Voltage-V Practical) circuit} \\
\hline
EX1 & 1.198 & 0.386 \\
\hline
EX2 & 0.858 & 0.332 \\
\hline
EX3 & 1.219 & 0.327 \\
\hline
EX4 & 1.209 & 0.234 \\
\hline
EX5 & 1.... | PMC2635613_table_3 | |
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|}
\hline
& \multicolumn{4}{|l|}{\textbf{Questionnaire return}} \\
\hline
& \textbf{Incomplete months for all nine} & \textbf{Complete months for all nine} & \textbf{Incomplete 9 months for 3, 6, and} & \textbf{Complete 9 months for 3, 6, and} \\
\hline
attende... | PMC2636800_table_0 | |
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|l|l|l|l|l|l|}
\hline
\textbf{Protein or gene} & \textbf{Ac} & \textbf{Ad} & \textbf{Na} & \textbf{Hc} & \textbf{Ans} & \textbf{Ass} & \textbf{Tc} & \textbf{Bm} & \textbf{Di} & \textbf{Ov} \\
\hline
ATP6 & 85.9 & 85.4 & 86.9 & 78.8 & 73.3 & 74.3 & 74.8 & 19.8 & 2... | PMC2656527_table_2 | |
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|}
\hline
& \multicolumn{3}{|l|}{\textbf{Odds ratio Age (95\% at menarche, confidence years interval)a, b}} \\
\hline
\\
\hline
\textbf{Tumor characteristic} & \textbf{11} & \textbf{$>$ 11 and 13} & \textbf{$>$ 13 and 14} \\
\hline
\multicolumn{4}{|l|}{Tumor s... | PMC2656904_table_2 | |
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|}
\hline
\textbf{Factor} & \textbf{R2} & \textbf{P-value} \\
\hline
Fasting plasma glucose & 0.0120 & NS \\
\hline
HbA1c & 0.0731 & .040 \\
\hline
Systolic blood pressure & 0.0133 & NS \\
\hline
Diastolic blood pressure & 0.0301 & NS \\
\hline
Total cholesterol (TC)... | PMC2656910_table_0 | |
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|l|l|}
\hline
\textbf{COG id} & \textbf{Description} & \multicolumn{2}{|l|}{\textbf{Mature}} & \multicolumn{2}{|l|}{\textbf{Infant}} & \textbf{Metastat value q-} \\
\hline
& & \textbf{Mean abundance (\%)} & \textbf{stderr} & \textbf{Mean abundance (\%)} & \text... | PMC2661018_table_2 | |
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|}
\hline
& \textbf{Saturated fatty acids} & \textbf{Linoleic acid (omega 6)} & \textbf{Total omega 3} & \textbf{Monounsaturated fatty acids} \\
\hline
Corn oila & 13 & 61 & 1 & 26 \\
\hline
Canola oila & 6 & 20 & 10 & 62 \\
\hline
n-3 supp.b & 9 & 6 & 63 & 21 \... | PMC2669087_table_1 | |
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|l|l|}
\hline
& \multicolumn{6}{|l|}{\textbf{DNA sequence identity thresholds defining a cassette-type (\%)}} \\
\hline
& \textbf{99} & \textbf{97} & \textbf{95} & \textbf{90} & \textbf{80} & \textbf{70} \\
\hline
Number of cassette-types & 3354 & 2980 & 2774 &... | PMC2674596_table_0 | |
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|l|}
\hline
Relative amount, \% & L1 & L2 & H1 & H2 & H3 \\
\hline
Human & 19.0 & 37.0 & 31.0 & 11.0 & 3.0 \\
\hline
Chimp & 22.6 & 36.6 & 25.4 & 13.2 & 2.1 \\
\hline
Dog & 23.8 & 35.5 & 23.7 & 13.4 & 3.6 \\
\hline
Overall average & 21.8 & 36.4 & 26.7 & 12.5 & 2.... | PMC2678159_table_0 | |
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|}
\hline
\textbf{Chemicals} & \textbf{Dm without synergists} & \textbf{Dm with PBO} & \textbf{Dm with DEF} \\
\hline
propoxur & 1.97 (1.78–2.19) & 0.27 (0.17–0.42) & 1.01 (0.83–1.24) \\
\hline
DEET & 1189 (1088–1299) & 611 (596–629) & 1078 (1005–1155) \\
\hline
mi... | PMC2680852_table_0 | |
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|}
\hline
& \textbf{Cases (n = 547) (\%)} & \textbf{Controls (n = 544) (\%)} & \textbf{ORb (95\% CI)} \\
\hline
\multicolumn{4}{|l|}{Menopausal status} \\
\hline
Premenopausal & 187 (34.2) & 230 (42.3) & 1.0 \\
\hline
Postmenopausal & 360 (65.8) & 314 (57.7) & 0.7... | PMC2680904_table_1 | |
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|}
\hline
\textbf{PON1 Premenopausal Postmenopausal Controls, Cases Controls, Cases Q192R Local, OR Advanced, OR Local, OR Advanced, OR by by (95\% (95\% (95\% (95\% n n stage stage n n (\%) (\%) (\%) (\%) CI)a CI)a CI)a CI)a n n (\%) (\%)} & \textbf{128 144 196 ... | PMC2680904_table_6 | |
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|}
\hline
& \textbf{All patients (n)} & \textbf{Group I (n)} & \textbf{Group II (n)} \\
\hline
Total no of patients & 50 & 30 & 20 \\
\hline
Cerebral Palsy & 18 & 11 & 7 \\
\hline
Duchenne muscular dystrophy & 18 & 12 & 6 \\
\hline
Spinal muscular atrophy & 8 & 3 ... | PMC2685769_table_0 | |
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|}
\hline
\textbf{Profiles} & \textbf{Characterization of the cluster defining the profile} \\
\hline
Professional & contacts at work have highest median as compared to other locations: m11 = max {m1i:i = 1,…,6} \\
\hline
School & contacts at school have highest median... | PMC2691957_table_1 | |
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|}
\hline
\textbf{Effect} & \textbf{Pillai(df)} & \textbf{Approximate F(df)} & \textbf{P-value} \\
\hline
Age & 0.99(1) & 48.28 (25,9) & ,0.0001 \\
\hline
Experience & 0.76(1) & 1.17 (25,9) & 0.43 \\
\hline
Age*Experience & 0.87(1) & 2.46(25,9) & 0.08 \\
\hline
\en... | PMC2702002_table_2 | |
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|l|l|l|}
\hline
& \multicolumn{7}{|l|}{\textbf{UCP2 Genotype}} \\
\hline
& \textbf{n} & \textbf{AA} & \textbf{n} & \textbf{GA} & \textbf{n} & \textbf{GG} & \textbf{p} \\
\hline
Gender (M/F) & 140 & 102/38(72.9\%M) & 410 & 309/101(75.4\%M) & 351 & 292/59 (83.2\%... | PMC2702310_table_0 | |
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|}
\hline
& \textbf{Physicians (n = 900)} & \textbf{Nurses (n = 277)} \\
\hline
Percent (regularly, that occasionally, use dietary or supplements seasonally) & 72\% & 89\% \\
\hline
Percent supplements regular users of dietary & 51\% & 59\% \\
\hline
Recommend to pa... | PMC2714854_table_0 | |
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|}
\hline
\textbf{Study} & \textbf{Outcome} & \textbf{Parameter interval estimate and 95\% confidence} \\
\hline
\multicolumn{3}{|l|}{Mortality 2° to COPD} \\
\hline
Ishida W, et al., Japan, 2007 [23] & Decreased mortality 2° to COPD in statin users & Inverse dispens... | PMC2716302_table_0 | |
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|}
\hline
Age (years) & 62 $\pm$ 18 (19 to 100) \\
\hline
Female/male & 83/97 \\
\hline
SAPS II & 37 $\pm$ 18 (9 to 103) \\
\hline
Mortality & 19\% (35 out of 180 patients) \\
\hline
Cirrhosis & 6 \\
\hline
Cancer & 45 \\
\hline
Community-acquired/postoperative periton... | PMC2717471_table_0 | |
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|}
\hline
& \multicolumn{2}{|l|}{\textbf{Known}} & \multicolumn{2}{|l|}{\textbf{Unknown}} \\
\hline
\textbf{Category*} & \textbf{Duplicated} & \textbf{Retrotransposed} & \textbf{Single-exon pseudogene} & \textbf{Multi-exon pseudogne} \\
\hline
Unsupported & 507 ... | PMC2724416_table_1 | |
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|}
\hline
& \textbf{Fibromyalgia} & \textbf{RA/SLE} & \textbf{Major depressiona} & \textbf{Healthy controls} \\
\hline
Number analyzed & 202 & 51 & 11 & 213 \\
\hline
Age, years & 51 $\pm$ 10.5 & 49 $\pm$ 13.1a & 46 $\pm$ 11.4b & 43 $\pm$ 14.0c \\
\hline
Gender ... | PMC2745803_table_1 | |
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|}
\hline
& \textbf{Diana-microT} & \textbf{PicTar} & \textbf{TargetScan 4.2} \\
\hline
Diana-microT & 22391 & 8882 & 10651 \\
\hline
PicTar & & 17135 & 12902 \\
\hline
TargetScan 4.2 & & & 19299 \\
\hline
\end{tabular}}
\end{table} | PMC2752464_table_1 | |
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|}
\hline
\textbf{Treatment Comparison} & \multicolumn{2}{|l|}{\textbf{Mixed Treatment Comparison}} & \multicolumn{2}{|l|}{\textbf{Adjusted Indirect Comparison}} \\
\hline
& \textbf{Odds Ratio} & \textbf{95\% Credible Interval} & \textbf{Odds Ratio} & \textbf{95... | PMC2760541_table_4 | |
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|l|}
\hline
\textbf{Rs10954213} & \multicolumn{2}{|l|}{\textbf{Allele}} & \multicolumn{3}{|l|}{\textbf{Genotype}} \\
\hline
\textbf{Group} & \textbf{A} & \textbf{G} & \textbf{AA} & \textbf{AG} & \textbf{GG} \\
\hline
BPD & 129 & 153 & 33 & 63 & 45 \\
\hline
C & 1... | PMC2760574_table_5 | |
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|}
\hline
\textbf{Genome/$\Delta$ bit score to 2nd hit1} & \textbf{R2} & \textbf{P} & \textbf{$\Delta$ $\sigma$ Heterokont} & \textbf{$\Delta$ $\sigma$ Reds} \\
\hline
P. ramorum/5\% & 0.714 & 0.007 & 2.71 & -0.12 \\
\hline
P. sojae/5\% & 0.717 & 0.007 & 2.67 & -... | PMC2770532_table_2 | |
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|l|l|}
\hline
& \multicolumn{2}{|l|}{\textbf{Mean Amplitude (mV) (300–800 ms)}} & \multicolumn{2}{|l|}{\textbf{Peak Amplitude (mV) (jackknifed values)}} & \multicolumn{2}{|l|}{\textbf{Peak Latency (ms) (jackknifed values)}} \\
\hline
\textbf{Condition} & \textbf... | PMC2777337_table_0 | |
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|}
\hline
\textbf{PCT test} & \textbf{Cutoff 0.5 ng /mL} & \textbf{Cutoff 2.0 ng/mL} & \textbf{Cutoff 10 ng/mL} \\
\hline
Sensitivity & 0.52 [0.37–0.67] & 0.20 [0.10–0.34] & 0.02 [0.00–0.13] \\
\hline
Specificity & 0.76 [0.66–0.83] & 0.91 [0.84–0.95] & 0.97 [0.92–0... | PMC2792948_table_0 | |
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|}
\hline
& \textbf{Perceived Factor susceptibility 1} & \textbf{Perceived Factor severity 2} \\
\hline
\\
\hline
Adolescent alcohol use outside home & 0.834 & 0.182 \\
\hline
Worries about adolescent alcohol use & 0.843 & 0.104 \\
\hline
Approved age for alcohol u... | PMC2809065_table_1 | |
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|}
\hline
\textbf{Parameter} & \textbf{Coefficient} & \textbf{Standard error} & \textbf{95\% Wald CI} & \textbf{P value} \\
\hline
(Intercept) & 6.816 & 0.0386 & 6.740 - 6.891 & $<$ 0.001 \\
\hline
Year 2009 & -3.907 & 0.2034 & -4.306 - -3.508 & $<$ 0.001 \\
\hli... | PMC2823607_table_3 | |
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|}
\hline
& \textbf{Isolated (n = 103) nurses} & \textbf{Non-isolated (n = 94) nurses} & \textbf{p value} \\
\hline
\multicolumn{4}{|l|}{Age categories (years)} \\
\hline
20 - 39 & 18 (17.5) & 24 (26.1) & Chi-square test for trend = 0.176, df = 1, p = 0.675. \\
\h... | PMC2823612_table_2 | |
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|}
\hline
\textbf{Time [days]◆:} & & \textbf{0} & \textbf{28} & \textbf{35} \\
\hline
Treatment group & Animal \\
\hline
Vaccinated & V1 & 0.057* & 0.185 & 0.736 \\
\hline
& V2 & 0.056 & 0.267 & 0.476 \\
\hline
& V3 & 0.054 & & 0.223 \\
\hline
& V4 & 0.051 &... | PMC2824702_table_1 | |
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|}
\hline
& \textbf{IL-2} & \textbf{IL-2+ART} & \textbf{Control} & \textbf{Total} \\
\hline
\multicolumn{5}{|l|}{Age (years)} \\
\hline
Median & 35 & 35 & 36 & 36 \\
\hline
Interquartile range & & & & 30–44 \\
\hline
Gender (\% female) & 19.1 & 14.9 & 17.6 & ... | PMC2826395_table_0 | |
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|l|}
\hline
\textbf{Gene} & \textbf{Coverage} & \textbf{\#G} & \textbf{\#A} & \textbf{Freq. of G} & \textbf{aa change} \\
\hline
Gabra3 & 679 & 631 & 48 & 92.93\% & I/M \\
\hline
Elavl2 & 633 & 9 & 624 & 1.422\% & I/V \\
\hline
Elavl2 & 625 & 15 & 610 & 2.400\% &... | PMC2831006_table_5 | |
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|l|}
\hline
\textbf{E. chaffeensis protein} & \textbf{OM (Da)} & \textbf{PM (Da)} & \textbf{MS (Da)} & \textbf{Mass (OM-PM difference in Da)} & \textbf{Mass (PM-MS difference in Da)} \\
\hline
Native TRP47 & ,47,000 & 32,925.5 & 33,104.5 & 14,075 & 179 \\
\hline
... | PMC2832021_table_0 | |
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|}
\hline
& \textbf{Initial individuals) 3 months (n = 583} & & \textbf{After individuals) 3 months (n = 559} \\
\hline
Variable & Unadjusted CI) Hazard Ratio (95\% & Adjusted (95\% CI) Hazard Ratio & Unadjusted CI) Hazard Ratio (95\% & Adjusted (95\% CI) Hazar... | PMC2835706_table_2 | |
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|}
\hline
\textbf{Variable} & \textbf{No. (\%)} \\
\hline
Mortality & 1 (1.7) \\
\hline
Myocardial infarction & 1 (1) \\
\hline
Target vessel reintervention & 4 (6) \\
\hline
Reoperation for bleeding & 2 (3) \\
\hline
Pleural effusion & 2 (3) \\
\hline
Pulmonary infect... | PMC2842890_table_1 | |
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|}
\hline
\textbf{Subscale} & \textbf{Patients postoperative (n = 151) 7 years} & \textbf{Reference group Postoperative (n = 65) 7 years} & \textbf{p-value} \\
\hline
SF-36 PF & 54 (27.2) & 69 (31.3) & 0.01 \\
\hline
SF-36 RP & 45 (44.6) & 60 (46.0) & 0.05 \\
\hlin... | PMC2847954_table_4 | |
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|}
\hline
\multicolumn{2}{|l|}{\textbf{(A) A DNA database.}} \\
\hline
\multicolumn{2}{|l|}{CCCTAATG} \\
\hline
\multicolumn{2}{|l|}{TTAATAAT} \\
\hline
\multicolumn{2}{|l|}{ATAATGCG} \\
\hline
\multicolumn{2}{|l|}{(B) All 5-patterns in the database.} \\
\hline
\multic... | PMC2848650_table_0 | |
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|}
\hline
\multicolumn{3}{|l|}{Total number of 16-year-olds in the city of Uppsala: n = 2,465} \\
\hline
\multicolumn{3}{|l|}{Participated in the screening procedure: n = 2,300} \\
\hline
\multicolumn{3}{|l|}{Delivered complete screening questionnaires: n = 2,270} \\... | PMC2853351_table_0 | |
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|}
\hline
\textbf{Compd} & \textbf{R1} & \textbf{R2} & \textbf{R3} & \textbf{IC50 TryR [mm]} \\
\hline
39 & Me & Me & 4’-Methylphenyl & 8.6 \\
\hline
40 & Me & CH2CH3 & Thiophen-2-yl & 12.8 \\
\hline
41 & Me & CH2CH3 & 2’-Fluoro-5’-Bromophenyl & 10.2 \\
\hline
42... | PMC2855869_table_2 | |
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|l|}
\hline
& & \multicolumn{2}{|l|}{\textbf{TeleAtlas}} & \multicolumn{2}{|l|}{\textbf{ArcView/NAVTEQ}} \\
\hline
\textbf{Address status} & \textbf{N} & \textbf{Error1} & \textbf{N (\%)2} & \textbf{Error1} & \textbf{N (\%)2} \\
\hline
Self-reported Post-E911 S... | PMC2867955_table_0 | |
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|l|l|}
\hline
\textbf{Clinical group} & \textbf{Controls (n = 27)} & \textbf{Not (n = Infected 118)} & \textbf{Infected (n = 74)} \\
\hline
& & & & Culture (n = 41) positive & Culture (n = 33) Negative \\
\hline
Duration antibiotic (days) of therapy & 0 (0,0) &... | PMC2868836_table_3 | |
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|}
\hline
\textbf{Theme} & \textbf{Descriptive terms (reference)} \\
\hline
Methods development that support sustainable & Health sustainability. designed participatory process.54 Health impacts points government Cities development programmes in Impact Impact and time ... | PMC2872568_table_1 | |
\begin{table}
\scalebox{0.60}{
\begin{tabular}{|l|l|l|l|}
\hline
& \textbf{All oligo (service) arrays} & \textbf{Oligo arrays following normal karyotype} & \textbf{Oligo arrays as first line test} \\
\hline
Total patients & 2414 & 1245 & 1169 \\
\hline
Abnormal patients & 585 (24\%) & 325 (26\%) & 260 (22\%) \\
\hline... | PMC2885406_table_2 |
End of preview. Expand in Data Studio
README.md exists but content is empty.
- Downloads last month
- 5